Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Meningitis, Cryptococcal

ClinicalTrials.gov lists 54 trials for Meningitis, Cryptococcal or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 11.

MeSH D016919 Infections C01 C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 4 Phase 1/2 Phase 1/2 2 Phase 2 Phase 2 7 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 6 Phase 4 Phase 4 5 Not applicable Not applicable 19 Observational Observational 8 Phase 1 Phase 1 4 Phase 1/2 Phase 1/2 2 Phase 2 Phase 2 7 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 6 Phase 4 Phase 4 5 Not applicable Not applicable 19 Observational Observational 8

Trials per phase

54 of the 54 trials are tagged with Meningitis, Cryptococcal itself; the rest are tagged with a narrower condition beneath it.

Get the Meningitis, Cryptococcal report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Meningitis, Cryptococcal trials start? (20)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 6

1993: 1 trials (Observational 1) 2000: 1 trials (Phase 2 1) 2005: 1 trials (Phase 2 1) 2006: 2 trials (Not applicable 1, Phase 2 1) 2007: 1 trials (Phase 2 1) 2009: 2 trials (Observational 1, Phase 4 1) 2010: 2 trials (Phase 4 1, Phase 1/2 1) 2011: 1 trials (Not applicable 1) 2012: 3 trials (Phase 4 1, Phase 3 1, Phase 2/3 1) 2013: 1 trials (Observational 1) 2015: 6 trials (Observational 3, Not applicable 1, Phase 3 1, Phase 1 1) 2016: 2 trials (Not applicable 1, Phase 4 1) 2017: 1 trials (Phase 2 1) 2019: 2 trials (Phase 2/3 1, Phase 1/2 1) 2020: 3 trials (Observational 2, Phase 3 1) 2021: 1 trials (Phase 1 1) 2022: 1 trials (Not applicable 1) 2023: 3 trials (Not applicable 1, Phase 4 1, Phase 3 1) 2024: 1 trials (Phase 2 1) 2025: 1 trials (Phase 2/3 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2025 1
2024 1
2023 3
2022 1
2021 1
2020 3
2019 2
2017 1
2016 2
2015 6

No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Meningitis, Cryptococcal trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 4
Phase 1/2 2
Phase 2 7
Phase 2/3 3
Phase 3 6
Phase 4 5
Not applicable 19
Observational 8

How many Meningitis, Cryptococcal trials are recruiting? (6)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 1
Recruiting 4
Enrolling by invitation 1
Completed 35
Terminated 2

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Meningitis, Cryptococcal trials? (7)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Pfizer 11
National Institute of Allergy and Infectious Diseases (NIAID) 8
National Hospital for Tropical Diseases, Hanoi, Vietnam 3
ANRS, Emerging Infectious Diseases 2
Matinas BioPharma Nanotechnologies, Inc. 2

Which drugs are being tested for Meningitis, Cryptococcal? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
AMPHOTERICIN B 18
Flucytosine 11
Itraconazole 2
Amphotericin B Deoxycholate 2
Efungumab (Mycograb) 2

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Fluconazol 25
liposomal Amphotericine B 2
MAT2203 2
Oteseconazole with Flucytosine - antifungal therapy 4 1
10-Week Fluconazole 1

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Meningitis, Cryptococcal trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Anemia 110 2
Grade 4 Serious AEs 80 1
Grade 3 Serious AEs 78 1
Hyponatremia 36 2
Meningitis cryptococcal 35 2

Which publications cover Meningitis, Cryptococcal? (77)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages